Sat.Sep 03, 2022 - Fri.Sep 09, 2022

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies. In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. They relied so much on a new drug that they tried to market a product with bad science behind it.

Pharma 210
article thumbnail

Owkin’s AI solutions for breast and colorectal cancer receive European approval

MedCity News

The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.

Patients 140
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The discovery of a new and compounding cybersecurity threat to pharmacies

pharmaphorum

Sam Crowther, founder and CEO of cybersecurity company Kasada, tells us about a recent discovery his company made that revealed tens of thousands of accounts with prescription drug attachments in major online pharmacies had been compromised. While performing analysis for a client of online accounts for sale, Kasada uncovered a new and illegal way bots are being used – to steal pharmacy customers’ accounts and resell prescriptions on a secondary market for in-demand substances, such as Oxyc

article thumbnail

The 2022 PharmaVoice 100

PharmaVoice

From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.

137
137
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

AstraZeneca on the hunt for new acquisitions

Pharmaceutical Technology

Following AstraZeneca’s success in vaccine development during the Covid-19 pandemic , the pharmaceutical giant is now looking to expand its scope through acquisitions across a range of indications, says CEO Pascal Soriot. “We want to be a sustainably growing company. Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”.

FDA 114
article thumbnail

3 care categories that matter in connected health care

MedCity News

Medical IoT is forecast to grow from $41 billion in 2020 to $188 billion by 2028. The growth is for a good reason: Connected medical devices, combined with the right software, can improve conditions and delivery, optimize care and devices, and save lives.

Medical 132

More Trending

article thumbnail

Surface Coating Rapidly Kills Pathogens, Lasts Months

Medgadget

A team at the University of Michigan has developed a coating for frequently touched surfaces that can rapidly kill a wide array of pathogens, including MRSA and SARS-CoV-2. The technology incorporates polyurethane that contains crosslinked compounds from essential oils with wide-spectrum anti-microbial action. The researchers fine-tuned the crosslinking process so that the oils were available to kill microbes but not sufficiently free to evaporate rapidly.

Food 112
article thumbnail

Roche to acquire biopharma firm Good Therapeutics for $250m

Pharmaceutical Technology

Roche has signed a definitive merger agreement for the acquisition of US-based biopharmaceutical company Good Therapeutics for an upfront payment of $250m in cash. Good Therapeutics focuses on the development of PD-1-regulated IL-2 drugs that are based on innovative conditionally active drug technology. With the takeover, Roche will attain rights to a conditionally active, PD-1-regulated IL-2 programme of Good Therapeutics.

Biopharma 111
article thumbnail

Conversational AI helps alleviate impact of nurse shortages

MedCity News

One organization piloted a smart speaker system in its spinal injuries unit. Over the course of four weeks, patients interacted with the automated assistant more than 5,000 times. Sixty-three percent of nurses on the unit found the pilot improved their ability to deliver and prioritize patient care.

Patients 130
article thumbnail

NICE says no to Lynparza in prostate cancer, creating UK access divide

pharmaphorum

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. The health technology assessment (HTA) authority said that the PARP inhibitor “is not cost-effective at its current price” as a treatment for BRCA-positive prostate cancer that has spread to other parts of the body and relapsed after prior hormonal therapy.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Pneumatic Assistive Device for People with Disabilities

Medgadget

Researchers at Rice University have developed a pneumatic assistive device for people with disabilities. The technology includes an air pump that is mounted in the wearer’s shoe, providing pneumatic power with each step. This power is stored in a wearable belt that includes an “arm” that can reach out and grip items when activated. The device may be very practical for people with arm weakness who struggle to lift objects.

Medical 109
article thumbnail

Bayer agrees to pay $40m to resolve claims on three drugs

Pharmaceutical Technology

Bayer has agreed to make a payment of $40m for settling claims over the alleged violations of the False Claims Act linked to three drugs, Trasylol, Avelox and Baycol, the US Department of Justice said in a press statement. The settlement comes after a former Bayer employee, Laurie Simpson, filed two 'whistleblower' lawsuits against the company. These litigations were filed under the qui tam or whistleblower provisions of the False Claims Act, which facilitate private citizens to file lawsuits ag

Safety 105
article thumbnail

The divorce of care from health in healthcare: Reuniting American healthcare

MedCity News

The drive to “fix healthcare” is ingrained in our society. Politicians speak about it regularly, consumers struggle to understand it, and yet the “how” of fixing it is delivered with ambiguity and jargon. With increased urgency to improve healthcare, everyone is now laser focused on this topic. But, over time, the term “healthcare” itself has lost the part about care.

article thumbnail

Ypsomed brings Sidekick on board to fight self-injection anxiety

pharmaphorum

Asking patients with chronic conditions to regularly inject themselves can be challenging, causing needle anxiety and worry that they may not carry out the procedure correctly, which can reduce compliance. Now, a partnership between Ypsomed and Sidekick Heath aims to tackle that problem. Ypsomed is a top developer of injection and infusion systems, so knows a lot about the difficulties that patients can face when getting to grips with these medical devices, particularly when they are just starti

Patients 104
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

How to Distribute Content to Doctors (Plus, 7 Tips on Email Marketing to Doctors)

Healthcare Success

Welcome to step four of our “Marketing to Doctors” blog series. This comprehensive playbook is designed to help people in virtually every sector (e.g., healthcare businesses, device and supply companies, SaaS, etc.) market their products and services directly to doctors, physicians, surgeons, and other healthcare professionals. If you haven’t read steps 1-3, I highly recommend doing so.

Doctors 103
article thumbnail

India grants approval for Bharat Biotech’s intranasal Covid-19 vaccine

Pharmaceutical Technology

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. A recombinant replication-deficient adenovirus vectored vaccine, iNCOVACC has a prefusion stabilised spike protein and is claimed to be the first intranasal vaccine globally to obtain primary two-dose schedule approvals.

article thumbnail

FTC accuses data company of tracking visits to reproductive health clinics

MedCity News

Kochava allegedly sold geolocation data from hundreds of millions of cell phones that showed people’s visits to reproductive health clinics, places of worship, homeless and domestic violence shelters and addiction recovery facilities. .

126
126
article thumbnail

Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants

PharmExec

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Clinical registry data, a valuable source of real-world data

PharmaVoice

Real-world data (RWD) from clinical drug registries can and should be used throughout the drug development lifecycle. At all stages, registries ensure that assumptions about the current standard of care are accurate and evidence-based.

98
article thumbnail

US FDA grants Orphan Drug status to Avacta’s drug for soft tissue sarcoma

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin. This approach aids the therapy to be activated mainly in the tumour, sparing healthy tissue from exposure.

article thumbnail

Walmart, UnitedHealth Group form 10-year value-based care partnership

MedCity News

Through the collaboration, UnitedHealth Group’s Optum will use its analytics and support tools to help Walmart Health clinicians deliver value-based care to Medicare Advantage beneficiaries. The partnership is starting at 15 locations in Florida and Georgia with the potential to grow in the future.

124
124
article thumbnail

Telehealth cuts overdoses for opioid users, says study

pharmaphorum

Greater use of telehealth services forced by COVID-19 seems to have benefitted people with opioid use disorder (OUD), leading to longer times on treatment and reduced risk of overdose, according to a new study. The researchers examined data from two groups of Medicare patients, one treated for OUD before the pandemic, and another who were treated after COVID-19 took hold, with greater use of telehealth support to complement in-person care.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

A Pet Owner’s Guide to Understanding Leptospirosis in Dogs

Celeritas

Leptospirosis is a rare and dangerous virus found in temperate and tropical regions. It is highly threatening to outdoor pets such as dogs. Although less than 1% of dogs are affected by Leptospirosis, it is not to be dismissed because exposure to it can harm your pet’s health. The following article will include: What is Leptospirosis? Stages of Leptospirosis and their Symptoms.

article thumbnail

Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure

Pharmaceutical Technology

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Initially, the companies partnered to identify new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s artificial intelligence (AI)-powered platform in December 2019.

article thumbnail

uMETHOD, Getlabs partner to make personalized cognitive decline care plans accessible in Arizona

MedCity News

uMETHOD, which provides precision medicine software to treat cognitive decline, tapped at-home diagnostics provider Getlabs to supply mobile phlebotomies for its patients in Arizona. Blood tests are an essential part of the personalized care plans that uMETHOD provides, and the partnership seeks to make these tests accessible to patients with cognitive decline.

Medicine 114
article thumbnail

AI Device Monitors Breathing to Diagnose Parkinson’s

Medgadget

Researchers at MIT have developed an AI system that can diagnose Parkinson’s disease and track its progression, simply by monitoring someone’s breathing patterns as they sleep. The device looks like an internet router and can be mounted on the wall in a bedroom. It emits radio waves and then a neural network analyzes the reflected waves to assess breathing patterns.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Dolutegravir shows promise in pregnancy

European Pharmaceutical Review

Comparing the use of common antiretroviral therapy (ART) regimens in pregnancy suggests that dolutegravir-based regimens have a higher probability of human immunodeficiency virus type 1 (HIV-1) viral suppression at delivery. In a study published in the New England Journal of Medicine , researchers compared the effectiveness and safety of dolutegravir-based ART to five ART regimens recommended for use in pregnancy in the US and Europe: atazanavir–ritonavir, darunavir–ritonavir, oral rilpivirine,

article thumbnail

Are radiopharmaceuticals the next breakthrough in oncology?

pharmaphorum

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies. The article also outlines some of the challenges remaining to be tackled. Radiotherapy dates back more than a hundred years, yet it still remains a core part of cancer treatment today.

article thumbnail

3 measures healthcare facilities should take to reduce maternal mortality rates post-Roe

MedCity News

Especially today, when more mothers’ health may be at risk, we can reduce potential harm and save thousands of lives through more evidence-based education, continuous training, and awareness that will help our obstetric care teams make informed and accurate medical decisions with effective interventions that mitigate complications early and often.

Education 114
article thumbnail

Reducing Blind Spots in the Pharma Supply Chain

PharmaTech

Expanded use of data analytics can help to avoid disruptions, but the possibilities cannot be realized without sufficient investment and direct human involvement.

Pharma 98
article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.